Last reviewed · How we verify

NCT04097964

Examining the Effectiveness of the FaCES Adolescent SBIRT Intervention

Completed NA Last updated 22 October 2021
What this trial tests

NA trial testing brief intervention in Adolescent Health Services in 1,226 participants. Completed in 30 June 2021.

Timeline
15 March 2018
Primary endpoint
30 June 2021
30 June 2021

Quick facts

Lead sponsorFriends Research Institute, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment1,226
Start date15 March 2018
Primary completion30 June 2021
Estimated completion30 June 2021
Sites4 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Friends Research Institute, Inc.

Who can join

Adults 12 to 17, any sex, with Adolescent Health Services or Adolescent Behavior. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will utilize a stepped wedge cluster randomized design to examine the effectiveness of the full FaCES (Facilitating Change for Excellence in SBIRT) adolescent SBIRT change package. Primary care providers will be randomized as to when they receive training and begin delivery of FaCES with their 12 to 17 year old patients, which includes targeted feedback based on the patient's endorsed substance use level on the S2BI screening instrument.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of brief intervention

Trials testing the same drug.

Other Friends Research Institute, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04097964.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing